Next Phase Newsletter

The firm is a private equity investment and corporate finance advisory firm headquartered in Singapore with a presence in the US, India, Malaysia and London. The firm makes global investments into life

science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.1m to $0.5m.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and supplier companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has flexible investment criteria but the firm is less interested in companies whose business focus is restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The group is an angel network based in California. The group makes investments across a variety of sectors, including technology and life sciences. Members of the fund invest individually, and therefore investments made by the group are highly varied in size but are typically in the hundreds of thousands of dollars, up to $1M. Investments are in the form of equity or convertible loans, and are typically provided in early venture rounds. The group invests in companies in the USA and Canada and will also consider opportunities outside North America on an opportunistic basis.

Within the life science space, the group invests broadly in healthcare IT, healthtech, diagnostics, medical devices and therapeutics. The group also invests in repurposed drugs and veterinary drugs. The group prefers to invest in companies that have at least developed a working prototype of their product and/or done animal trials.

The group seeks management teams with prior industry success. Additionally, the group prefers to make investments with reasonable horizons and is therefore interested in proposals that provide strong possibilities for exits in 5 years or less. The group will participate in seed, series A and occasionally Series B rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The firm is an ophthalmic medical device company headquartered in Beijing with offices in Hong Kong and Europe. The firm is actively seeking external innovations in the ophthalmic device space and is looking for early-stage companies that have strategic alignment with the firm. The firm works with early-stage startups using a variety of structures, including equity investments, in-licensing, acquisition, joint-venture and distribution. The firm can help companies grow in China market, where they can leverage their resources in many ways, like supporting CFDA approval, engineering, manufacturing, distribution and after-sale services. The firm is a multi-stage investor and is interested in new technologies worldwide.

The company invests in ophthalmic medical devices that have proof of concept done and a prototype ready.

The company does not have specific requirements for the company’s management team. The firm will consider taking board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm based in China makes early-growth stage investments, preferably from angel/seed to B), but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune disease, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC based in Western Europe is currently raising a new fund which will be focused specifically on therapeutics. Around 50% of their new fund will be dedicated to venture building, and the other half will be dedicated to traditional venture investing. The firm will invest in European and Israeli companies, and will invest from lead identification to IND-stage, although the firm is open to investing in clinical-stage companies. The firm will invest between $5-25M per investment (seed, series A, series B).

The firm is looking to invest only in therapeutics. Within therapeutics, the firm is agnostic to modality. The firm is primarily interested in the indications of oncology (particularly glioblastoma, pancreatic cancer and sarcoma), rare diseases and CNS disorders, particularly those with a genetic origin. The firm is interested in First-In-Class and Best-In-Class therapeutics, but may consider repurposed therapeutics for CNS only.

The firm is interested in investing in experienced management teams. The firm prefers to co-invest, and may take a board seat, but does not require it.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Asia with additional offices in the USA makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based family office has started to make direct investments in companies in the life sciences space and looks to potentially make additional investments. Currently, the firm is most interested in medical device or diagnostics companies.

The firm is most interested in medical devices and diagnostics. The firm is opportunistic and will consider all types of technologies and indications.

The firm has no specific company requirements and prefers to invest alongside syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.